#United States #Drug Discovery #Billerica #Momentum Biotechnologies #CHIPP

Momentum Biotechnologies Introduces Pioneering CHIPP Technology

Momentum Biotechnologies, a distinguished organization in the field of contract research, has recently launched CHIPP, an advanced technology aimed at improving drug discovery through high-throughput target deconvolution. This innovative approach utilizes mass spectrometry to provide a comprehensive analysis of drug-target interactions, enhancing the capacity for drug development.

What is CHIPP?

CHIPP, which stands for chaotrope-induced protein precipitation and proteome profiling, is designed to offer scientists a sensitive, scalable, and label-free assay. By leveraging the power of mass spectrometry, CHIPP allows for the automated profiling of numerous compounds simultaneously, making it a valuable tool for both target identification and selectivity analysis. The ability to analyze hundreds of test compounds efficiently is a significant advancement over existing methodologies that are often limited in scope and depth.

Enhancing Drug Discovery Workflows

Hannes Hahne, the President of Momentum's European operations, expressed enthusiasm about the launch, stating, "We are very excited to launch our new CHIPP technology for scalable and comprehensive target profiling." He highlighted that the CHIPP assay significantly boosts both data depth and throughput, enabling research teams to gather more information in less time than previously possible. This shift in methodology offers a transformative advantage to scientific research, allowing for a broader exploration of potential drug candidates.

Can Ozbal, the Founder and CEO of Momentum Biotechnologies, echoed this sentiment, noting that CHIPP has the potential to change conventional drug discovery workflows radically. Researchers can now investigate a multitude of primary screening hits in a straightforward 96-well-plate configuration, rather than being constrained to only a handful of candidates for further profiling. Such flexibility not only assists clients but also accelerates the development of new therapeutic options.

Upcoming Showcase at ASMS Conference

The excitement surrounding CHIPP will be palpable at this year's American Society for Mass Spectrometry (ASMS) conference, where Momentum Biotechnologies will demonstrate this technology alongside their other service offerings. Scheduled for May 31 to June 4, 2026, in San Diego, California, the event will provide a platform for researchers to connect with Momentum's scientific team and learn more about CHIPP's capabilities. Interested parties can reach out via the Momentum website or directly via email to explore how CHIPP can fit into their research endeavors.

About Momentum Biotechnologies

Momentum Biotechnologies stands at the forefront of drug discovery, providing specialized mass spectrometry solutions to biopharmaceutical companies worldwide. Their extensive range of services includes high-throughput screening, bioanalysis, and proteomics, designed to assist clients in identifying, validating, and characterizing therapeutic leads. With a seasoned team boasting over two decades of experience, Momentum has established itself as one of the largest high-throughput mass spectrometry laboratories globally, boasting facilities both in Billerica, Massachusetts, and Freising, Germany. Visit momentum.bio for more information about their innovative solutions and services.

In conclusion, the introduction of CHIPP marks a significant step forward in drug discovery processes, enabling researchers to harness the power of mass spectrometry for enhanced profiling and analysis. Momentum Biotechnologies continues to lead the charge in revolutionizing the landscape of pharmaceutical research, promising to bring transformative changes to the industry.